Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from α-aminosuberic acid

Journal of Medicinal Chemistry

Volumn 49, Issue 26, 2006, Pages 7611-7622

  Kahnberg, Pia ^a   Lucke, Andrew J ^a   Glenn, Matthew P ^a   Boyle, Glen M ^b   Tyndall, Joel D A ^a   Parsons, Peter G ^b   Fairlie, David P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINOSUBERIC ACID; AMINO ACID DERIVATIVE; ANTINEOPLASTIC AGENT; CYSTEINE DERIVATIVE; CYTOTOXIC AGENT; CYTOTOXIN; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PROTEIN P21; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL KILLING; CELL SPECIFICITY; CELL SURVIVAL; CONTROLLED STUDY; DRUG CONFORMATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MASS SPECTROMETRY; MELANOMA CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; TISSUE SPECIFICITY;

ACETYLATION; AMINO ACIDS, DICARBOXYLIC; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; INHIBITORY CONCENTRATION 50; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845925314     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050214x     Document Type: Article

References (55)

1. Rodriquez, M.; Aquino, M.; Bruno, I.; De Martino, G.; Taddei, M.; Gomez-Paloma, L. Chemistry and biology of chromatin remodelling agents: state of art and future perspectives of HDAC inhibitors. Curr. Med. Chem. 2006, 13, 1119-1139.
2. (a) Marks, P. A.; Richon, V. M.; Kiyokawa, H.; Rifkind, R. A. Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 10251-10254.
3. (b) Rifkind, R. A.; Richon, V. M.; Marks, P. A. Induced differentiation, the cell cycle and the treatment of cancer. Pharmacol. Ther. 1996, 69, 97-102.
4. Leszczyniecka, M.; Roberts, T.; Dent, P.; Grant, S.; Fisher, P. B.; Differentiation, therapy of human cancer: basic science and clinical implications. Pharmacol. Ther. 2001, 90, 105-156.
5. (a) Lin, H. Y.; Chen, C. S.; Lin, S. P.: Weng, J. R.; Chen, C. S. Targeting histone deacetylase in cancer therapy. Med. Res. Rev. 2006, 26, 397-413.
6. (b) Vigushin, D. M.: Coombes, R. C. Histone deacetylase inhibitors in cancer treatment. Anti-Cancer Drugs 2002, 13, 1-13.
7. Marks, P. A.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nature 2001, 1, 194-202.
8. Richon, V. M.; Emiliani, S.; Verdin, S.; Webb, Y.; Breslow, R.; Rifkind, R. A.; Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3003-3007.
9. (a) Parsons, P. G.; Hansen, C.; Fairlie, D. P.; West, M. L.; Danoy, P. A. C.; Sturm, R. A.; Dunn, I. S.; Pedley, J.; Ablett, E. M. Tumor selectivity and transcriptional activation by azalaic bishydroxamic acid in human melanocytic cells. Biochem. Pharmacol. 1997, 53, 1719-1724.
10. (b) Qui, L.; Kelso, M. J.; Hansen, C.; West, M. L.; Fairlie, D. P.; Parsons, P. G. Antitumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br. J. Cancer 1999, 80, 1252-1258.
11. (a) Butler, L. M.; Agus, D. B.; Sher, H. I.; Higgins, B.; Rose, A.; Cordon-Cardo, C.; Thaler, H. T.; Rifkind, R. A.; Marks, P. A.; Richon, V. M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000, 60, 5165-5170.
12. (b) Kelly, W. K.; Marks, P. A. Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. 2005, 2, 150-157.
13. (a) Su, G. H.; Sohn, T. A.; Ryu, B.; Kern, S. E. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. 2000, 60, 3137-3142.
14. (b) Varghese, S.; Gupta, D.; Baran, T.; Jiemjit, A.; Gore, S. D.; Casero, R. A., Jr.; Woster, P. M. Alkyl-substituted polyaminohydroxamic acids: A novel class of targeted histone deacetylase inhibitors. J. Med. Chem. 2005, 48, 6350-6365.
15. Tsuji, N.; Kobayashi, M.; Nagashima, K.; Wakisaka, Y.; Koizumi, K. A new antifungal antibiotic, trichostatin. J. Antibiot. 1976, 29, 1-6.
16. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179.
17. Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreverible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 1993, 268, 22429-22435.
18. Darkin-Rattray, S. J.; Gurnett, A. M.; Myers, R. W.; Dulski, P. M.; Crumley, T. M.; Allocco, J. J.; Cannova, C.; Meinke, P. T.; Colletti, S. L.; Bednarek, M. A.; Singh, S. B.; Goetz, M. A.; Dombrowski, A. W.; Polishook, J. D.; Schmatz, D. M. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 13143-13147.
19. Yoshida, M.; Furumai, R.; Nishiyama, M.; Komatsu, Y.; Nishino, N.; Horinouchi, S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 2001, 48, S20-S26.
20. Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 87-92.
21. Murray, P. J.; Kranz, M.; Ladlow, M.; Taylor, S.; Berst, F.; Holmes, A. B.; Keavey, K. N.; Jaxa-Chamiec, A.; Seale, P. W.; Stead, P.; Upton, R. J.; Croft, S. L.; Clegg, W.; Elsegood, M. R. J. The synthesis of cyclic tetrapeptoid analogues of the antiprotozoal natural product Apicidin. Bioorg. Med. Chem. Lett. 2001. 11, 773-776.
22. (a) Taunton, J.; Collins, J. L.; Schreiber, S. L. Synthesis of natural and modified trapoxins, useful reagents for exploring histone deacetylase function. J. Am. Chem. Soc. 1996, 118, 10412-10422.
23. (b) Komatsu, Y.; Tomizaki, K.; Tsukamoto, M.; Kato, T.; Nishino, N.; Sato, S.; Yamori, T.; Tsuruo, T.; Furumai, R.; Yoshida, M.; Horinouchi, S.; Hayashi, H. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res. 2001, 61, 4459-4460.
24. (a) Marson, C. M.; Savy, P.; Rioja, A. S.; Mahadevan, T.; Mikol, C.; Veerupillai, A.; Nsubuga, E.; Chahwan, A.; Joel, S. P. Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J. Med. Chem. 2006, 49, 800-805.
25. (b) Lu, Q.; Wang, D. S.; Chen, C. S.; Hu, Y. D.; Chen, C. S. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J. Med. Chem. 2005, 48, 5530-5535.
26. Atadja, P.; Gao, L.; Kwon, P.; Trogani, N.; Walker, H.; Hsu, M.; Yeleswarapu, L.; Chandramouli, N.; Perez, L.; Versace, R.; Wu, A.; Sambucetti, L.; Lassota, P.; Cohen, D.; Bair, K.; Wood, A.; Remiszewski, S. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 2004, 64, 689-695.
27. Gregoretti, I. V.; Lee, Y. M.; Goodson, H. V. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J. Mol. Biol. 2004, 338, 17-31.
28. De Ruijter, A. J. M.; Van Gennip, A. H.; Caron, H. N.; Kemp, S. Van Kuilenburg, A. B. P. Histone deacetylases (HDACs): Characterization of the classsical HDAC family. Biochem. J. 2003, 370, 737-749.
29. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
30. Somoza, J. R.; Skene, R. J.; Katz, B. R.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B. C.; Verner, E.; Wynands, R.; Leahy, E. M.; Dougan, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; Swanson, R. V.; McRee, D. E.; Tari, L. W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 2004, 12, 1325-1334.
31. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E. C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkühler, C.; Di Marco, S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 15064-15069.
32. Wegener, D.; Hildmann, C.; Schwienhorst, A. Recent progress in the development of assays for histone deacetylase inhibitor screening. Mol. Genet. Metab. 2003, 80, 138-147.
33. Glenn, M. P.; Kahnberg, P.; Boyle, G. M.; Hansford, K. A.; Hans, D.; Martyn, A. C.; Parsons, P. G.; Fairlie, D. P. Antiproliferative and phenotype-transforming antitumor agents derived from cysteine. J. Med. Chem. 2004, 47, 2984-2994.
34. Grozinger, C. M.; Schreiber, S. L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 2002, 9, 3-16.
35. Kao, H. Y.; Lee, C. H.; Komarov, A.; Han, C. C; Evans, R. M. Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J. Biol. Chem. 2002, 277, 187-193.
36. Gao, L.; Cueto, M. A.; Asselbergs, F.; Atadja, P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 2002, 277, 25748-25755.
37. Gregoretti, I. V.; Lee, Y. M.; Goodson, H. V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 2004, 338, 17-31.
38. (a) G. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
39. (b) Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623.
40. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440-467.
41. Glenn, M. P.; Kelso, M. J.; Tyndall, J. D. A.; Fairlie, D. P. Conformationally homogeneous cyclic tetrapeptides: useful three dimensional scaffolds. J. Am. Chem. Soc. 2003, 125, 640-641.
42. Tsantili-Kakoulidou, A.; Panderi, I.; Csizmadia, F.; Darvas, F. Prediction of distribution coefficient from structure. 2. Validation of prolog D, and expert system. J. Pharm. Sci. 1997, 86 (10), 1173-1179.
43. Qiu, L.; Burgess, A.; Fairlie, D. P.; Leonard, H.; Parsons, P. G.; Gabrielli, B. G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell 2000, 11, 2069-2083.
44. Burgess, A. J.; Pavey, S.; Warrener, R.; Hunter, L. J.; Piva, T. J.; Musgrove, E. A.; Saunders, N.; Parsons, P. G.; Gabrielli, B. G. Upregulation of p21 (WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol. 2001, 60, 828-837.
45. Curtin, M. L. Synthesis of novel hydroxamate and non-hydroxamate histone deacetylase inhibitors. Curr. Opin. Drug Discovery Dev. 2004, 7, 848-868.
46. Accelrys, Inc. InsightII Modeling Environment, release 2000; Accelrys, Inc.: San Diego, CA, 2001.
47. Hlavacek, J.; Marcova, R.; Budesinsky, M. 1-deamino-1(15)-carba and -dicarba analogues of endothelin-1 Collect. Czech. Chem. Commun. 2000, 65, 407-424.
48. Greenstein, J. P.; Birnbaum, S. M.; Otey, M. C. Optical enantiomorphs of α-aminoadipic acid. J. Am. Chem. Soc. 1953, 75, 1994-1995.
49. Mori, K.; Sugai, T.; Maeda, Y.; Okazaki, T.; Noguchi, T.; Naito, H. Synthesis of the racemic and optically active forms of gizzerosine, the inducer of gizzard erosion in chicks. Tetrahedron 1985, 41, 5307-5311.
50. Rivard, M.; Malon, P.; Cerovsky, V. Resolution of D,L-2-aminosuberic acid via protease-catalysed ester hydrolysis. Amino Acids 1998, 15, 389-392.
51. Parsons, P. G.; Bowman, E. P. W.; Blakely, R. L. Selective toxicity of deoxyadenosine analogues in human melanoma cell lines. Biochem. Pharmacol. 1986, 35, 4025-4029.
52. Todaro, G. J.; Fryling, C.; De Larco, J. E. Transforming growth factors produced by certain human tumour cells: polypeptides that interact with epidermal growth factor receptors. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 5258-5262.
53. Chen, T. R. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp. Cell. Res. 1977, 104, 255-262.
54. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
55. Rubinstein, L. V.; Shoemaker, R. H.; Paull, K. D.; Simon, R. M.; Tosini, S.; Skehan, P.; Scudiero, D. A.; Monks, A.; Boyd, M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 1990, 82, 1113-1118.